SNDX - Syndax Pharmaceuticals Inc logo

Syndax Pharmaceuticals Inc

SNDX
Rev 206xtop 1%10Y
Compare SNDX Hold

Syndax Pharmaceuticals develops therapies for cancer, including Revuforj for acute leukemia and Niktimvo for chronic graft-versus-host disease. Its pipeline includes treatments for acute myeloid leukemia, metastatic colorectal cancer, and idiopathic pulmonary fibrosis.

โš•๏ธ Healthcare NASDAQ Listed 2016 $ USD
$1,000 invested 10 years ago โ†’$938today

Score Overview

1 Year
Score
Net Growth22.65%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth46.21%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score3.4
Net Growth-8x
Net Trend40%
Net Income Consistencyโ€”
Rev Growth80.38%
Rev Trend60%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-396.41%
Net Trend40%
Net Income Consistency
Rev Growth206x
Rev Trend50%
Revenue Consistency
All Time
Score
Net Growth-396.41%
Net Trend40%
Net Income Consistency
Rev Growth206x
Rev Trend50%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Syndax Pharmaceuticals Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. SNDX does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 13.57โ€”
1 Year2025-10-22
$ 15.11-10.19%
5 Years2021-10-22
$ 18.96-28.43%
10 Years2016-10-21
$ 14.47-6.22%
All Time2016-03-03
$ 12.0112.99%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 252M-$ 220M$ 547M
2025$ 172M-$ 285M$ 413M
2024$ 23M-$ 318M$ 582M
2023$ 0.00-$ 209M$ 577M
2022$ 126M-$ 143M$ 484M
2021$ 139M$ 24M$ 446M
2020$ 1M-$ 73M$ 293M
2019$ 1M-$ 55M$ 59M
2018$ 1M-$ 73M$ 80M
2017$ 2M-$ 60M$ 133M
IPO2016$ 1M-$ 44M$ 105M
SNDX - Syndax Pharmaceuticals Inc logo

Syndax Pharmaceuticals Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 1M to $ 172M and net income went from -$ 73M to -$ 285M. Revenue increased in 3 of those 5 years; net income in 2.

Across Syndax Pharmaceuticals Inc's full reported history, from 2016 to 2025, revenue grew from $ 1M to $ 172M and net income went from -$ 44M to -$ 285M. Revenue increased in 50% of the years measured; net income in 40%.

Syndax Pharmaceuticals Inc currently holds a 5-year HDB Score of 3.4 out of 10. How the HDB Score is calculated.

Membership

Explore SNDX with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies